Paul M Silva's most recent trade in Rapport Therapeutics Inc. was a trade of 10,925 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 35,000 | 35,000 | - | - | Director Stock Option (right to buy) | |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.42 per share. | 26 Feb 2021 | 2,218 | 12,666 (0%) | 0% | 212.4 | 471,148 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 210.13 per share. | 26 Feb 2021 | 1,026 | 11,640 (0%) | 0% | 210.1 | 215,593 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 212.51 per share. | 26 Feb 2021 | 915 | 10,115 (0%) | 0% | 212.5 | 194,447 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 211.45 per share. | 26 Feb 2021 | 610 | 11,030 (0%) | 0% | 211.5 | 128,985 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 213.12 per share. | 26 Feb 2021 | 231 | 9,884 (0%) | 0% | 213.1 | 49,231 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.57 per share. | 24 Feb 2021 | 864 | 15,964 (0%) | 0% | 217.6 | 187,980 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 213.12 per share. | 24 Feb 2021 | 452 | 15,268 (0%) | 0% | 213.1 | 96,330 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 214.32 per share. | 24 Feb 2021 | 258 | 15,010 (0%) | 0% | 214.3 | 55,295 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 211.80 per share. | 24 Feb 2021 | 244 | 15,720 (0%) | 0% | 211.8 | 51,679 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 216.25 per share. | 24 Feb 2021 | 126 | 14,884 (0%) | 0% | 216.3 | 27,248 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 211.75 per share. | 17 Feb 2021 | 2,740 | 21,123 (0%) | 0% | 211.8 | 580,195 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 211.82 per share. | 17 Feb 2021 | 2,343 | 18,196 (0%) | 0% | 211.8 | 496,294 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 212.62 per share. | 17 Feb 2021 | 1,368 | 16,828 (0%) | 0% | 212.6 | 290,864 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 210.05 per share. | 17 Feb 2021 | 584 | 20,539 (0%) | 0% | 210.0 | 122,669 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 210.45 per share. | 11 Feb 2021 | 1,288 | 24,073 (0%) | 0% | 210.5 | 271,060 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 211.32 per share. | 11 Feb 2021 | 210 | 23,863 (0%) | 0% | 211.3 | 44,377 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.16 per share. | 10 Feb 2021 | 651 | 25,361 (0%) | 0% | 214.2 | 139,418 | Common Stock |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,220 | 19,152 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 3,634 | 26,012 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Paul M. Silva | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 3,226 | 22,378 (0%) | 0% | 0 | Common Stock |